← Back to Clinical Trials
Recruiting NCT02900040

NCT02900040 Clinical Database Associated With a Biological Banking Accessible to Initiate Epidemiological and Translational Collaborative Researches in Kidney Transplantation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02900040
Status Recruiting
Phase
Sponsor Nantes University Hospital
Condition Kidney Transplantation
Study Type OBSERVATIONAL
Enrollment 30,000 participants
Start Date 1994-01
Primary Completion 2050-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
kidney transplantation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30,000 participants in total. It began in 1994-01 with a primary completion date of 2050-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The French DIVAT (standing for Données Informatisées et VAlidées en Transplantation in french, and in English "Computerized and VAlidated Data in Transplantation" ) cohort was Kicked off in 1994 by the Transplantation Urology Nephrology Institute of the Nantes University Hospital in France. The primary objective of this multicenter computerized database was to enable prospective clinical and epidemiological research studies concerning kidney transplant recipients, particularly focusing on mid- and long-term clinical outcomes, therapeutic strategies and public health issues. The patient-case system of the DIVAT cohort allows the monitoring of medical records of all patient-specific and allograft-specific data, including bio-banking since 2005. Data are collected from the date of transplantation until the graft failure, at each scheduled outpatient visit or hospital admission motivating by a new clinical, therapeutical or biological expression. The DIVAT cohort contains information on more than 11000 transplant recipients between 1994 and today, issued from 8 French university hospitals centers (the DIVAT Network is organized by a consortium agreement). 18% of all patients underwent retransplantation and 11% of all kidney transplants originated from living donors. The DIVAT network heavily works to ensure a high-quality data collection with the aim of exploring adequately the complex post-transplantation process. The Divat network encourage collaborations and enables interested researchers to submit a research project by completing a request form available on the DIVAT website (http://www.divat.fr/en) describing the context, objectives and design of the study

Eligibility Criteria

Inclusion Criteria: * over the age of 18 years * with renal transplant Exclusion Criteria: * minor * pediatric transplantation

Contact & Investigator

Central Contact

Magali Giral, PU-PH

✉ mgiral@chu-nantes.fr

📞 +33 (0)2 40 08 74 43

Principal Investigator

Magali Giral, PU-PH

PRINCIPAL INVESTIGATOR

Nantes Universuty Hospital

Frequently Asked Questions

Who can join the NCT02900040 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02900040 currently recruiting?

Yes, NCT02900040 is actively recruiting participants. Contact the research team at mgiral@chu-nantes.fr for enrollment information.

Where is the NCT02900040 trial being conducted?

This trial is being conducted at Lyon, France, Montpellier, France, Nancy, France, Nancy, France and 4 additional locations.

Who is sponsoring the NCT02900040 clinical trial?

NCT02900040 is sponsored by Nantes University Hospital. The principal investigator is Magali Giral, PU-PH at Nantes Universuty Hospital. The trial plans to enroll 30,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology